Professional
Added to YB: 2024-07-09
Pitch date: 2024-07-09
ACRS [bullish]
Aclaris Therapeutics, Inc.
+156.8%
current return
Author Info
Special Situation Investments focuses on event-driven trades and low risk arbitrage opportunities with short term catalysts. Sign up for the newsletter.
Company Info
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States.
Market Cap
$273.0M
Pitch Price
$1.25
Price Target
N/A
Dividend
N/A
EV/EBITDA
-1.66
P/E
-2.06
EV/Sales
6.86
Sector
Pharmaceuticals
Category
value
Aclaris Therapeutics, Inc. - $ACRS
$ACRS: Busted biopharma trading 30% below net cash. Largest shareholder BML Investment Partners aggressively buying, increasing stake 13% to 18.3%. Unclear catalyst: strategic review ongoing, possible pivot to shareholder value realization, or value in patents. Cash burn risk if continuing drug development. Intriguing insider confidence.
Read full article (2 min)